Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer
- Supplementary File 1:
ZIP-Document (ZIP, 237 KiB)
Ziouziou, H.; Paris, C.; Benizri, S.; Le, T.K.; Andrieu, C.; Nguyen, D.T.; Appavoo, A.; Taïeb, D.; Brunel, F.; Oueslati, R.; Siri, O.; Camplo, M.; Barthélémy, P.; Rocchi, P. Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer. Pharmaceutics 2021, 13, 623. https://doi.org/10.3390/pharmaceutics13050623
Ziouziou H, Paris C, Benizri S, Le TK, Andrieu C, Nguyen DT, Appavoo A, Taïeb D, Brunel F, Oueslati R, Siri O, Camplo M, Barthélémy P, Rocchi P. Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer. Pharmaceutics. 2021; 13(5):623. https://doi.org/10.3390/pharmaceutics13050623
Chicago/Turabian StyleZiouziou, Hajer, Clément Paris, Sébastien Benizri, Thi K. Le, Claudia Andrieu, Dang T. Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, and Palma Rocchi. 2021. "Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer" Pharmaceutics 13, no. 5: 623. https://doi.org/10.3390/pharmaceutics13050623